Sahajanand Medical Technologies IPO

Sahajanand Medical Technologies (SMT) is an R&D-driven manufacturer of high-end medical devices, specifically targeting Class III and Class C/D regulatory categories [PAGE 4]. Its business is divided into two primary segments:

• Vascular Intervention (VI): Includes coronary stents and balloons. This is the core driver, contributing ~60-68% of total revenue [PAGE 4].
• Structural Heart (SH): Includes TA VI and Occluders. This is a growing segment, contributing ~12-16% of revenue [PAGE 4].
• Others: Includes renal stents, peripheral DCBs, and traded products, contributing ~19-23% [PAGE 4].

Revenue is generated through a mix of direct, hybrid, and distributor-led models across 65-77 countries [PAGE 4]. A critical demand driver is the global shift toward minimally invasive cardiovascular procedures [PAGE 5].

The company operates in the global cardiovascular devices market, which is expected to grow from USD 26.3 billion in 2025 to USD 37.8 billion by 2030 (7.5% CAGR) [PAGE 5]. The industry is characterized by high entry barriers due to complex R&D requirements and stringent regulatory certifications (Class III/C/D) [PAGE 4, 5]. SMT positions itself as a global player with a presence in India, Europe, and the Rest of the World (RoW), though it faces intense competition from established global MedTech entities [PAGE 4, 10].

SMT’s moat is built on:

• Regulatory Barriers: The ability to manufacture and sell high-complexity Class III and C/D devices [PAGE 4].
• R&D Capabilities: A focus on platform technologies and clinically proven products [PAGE 5].
• Diversified Manufacturing: Three facilities located in India and Thailand [PAGE 4].

However, the "moat" is potentially narrowed by significant product concentration, where a single product line (Supraflex Cruz) dictates a massive portion of the top line [PAGE 10].

Analysis: While revenue and profit show strong upward trajectories, the Net Debt to EBITDA ratio has steadily increased from 0.86 to 1.12 over three years [PAGE 8]. Notably, for the three months ended June 30, 2026, while the company reported a PAT of ₹150.87 million, the Operating Cash Flow was actually negative at ₹(222.08) million [PAGE 8], suggesting potential seasonal working capital pressure or timing of collections.

The IPO is structured entirely as an Offer For Sale (OFS) of 13,822,116 equity shares, representing 13.60% of the pre-offer capital [PAGE 6]. There is no Fresh Issue mentioned to provide growth capital to the company.

• Key Sellers: Major institutional/PE shareholders including Samara Capital Markets (29.61% stake), NHPEA Sparkle (15.24%), and Kotak Pre-IPO Opportunities Fund (5.98%) [PAGE 7].
• Implication: This is primarily a liquidity event for early investors rather than a capital infusion for company expansion.

The disclosed objects of the offer are to carry out the Offer for Sale by the Selling Shareholders and to achieve the benefits of listing [PAGE 6]. No specific capital allocation for capacity expansion, debt repayment, or R&D is listed in the "Objects of the Offer" section provided.

There is a massive disparity in the acquisition costs of existing shareholders, which provides a strong signal regarding the company's valuation journey:

• Samara Capital: ₹46.40 per share [PAGE 11].
• NHPEA Sparkle: ₹97.58 per share [PAGE 11].
• Kotak Pre-IPO Fund: ₹262.46 per share [PAGE 11].
• Weighted Avg Cost (Last 3 years): ₹316.13 [PAGE 11].

The upcoming IPO price will be a significant step up from the entry prices of several major investors, indicating high expectations for the valuation.

• Single Product Concentration: The Supraflex Cruz product (part of the VI segment) contributed between 37% and 47% of total revenue in recent periods [PAGE 10]. Any regulatory or competitive hit to this one product would be catastrophic.
• Supplier Concentration: The top 10 suppliers accounted for ~59-64% of total purchases [PAGE 10].
• Litigation Risk: The company is facing material litigation/proceedings against it involving an aggregate amount of ₹1,319.69 million [PAGE 12]. This amount is nearly double the FY26 PAT (₹690.82 million).
• Cash Flow Volatility: As noted in Section 4, the recent quarter (June 2026) showed negative operating cash flow despite being profitable [PAGE 8].

The promoters include Bhargav Dhirajlal Kotadia (MD & CEO) and the Shree Hari Trust [PAGE 6]. While the board includes independent directors and a representative from Samara Capital Markets, the high concentration of selling interest from private equity funds suggests the immediate focus of the large shareholders is on exiting rather than long-term holding.

• Product Risk: Over-reliance on Supraflex Cruz [PAGE 10].
• Regulatory Risk: Dependence on maintaining complex medical device permits and potential pricing regulations [PAGE 10].
• Supply Chain Risk: High dependence on a small number of suppliers [PAGE 10].
• Legal Risk: Significant outstanding litigation [PAGE 12].

SMT is a high-growth MedTech company operating in a structurally expanding global market. Its ability to scale from a ₹9,000m to a ₹12,000m revenue business in three years is impressive. However, the business quality is tempered by a heavy reliance on a single product line and a significant litigation overhang. The financial performance is healthy but shows signs of increasing leverage and working capital volatility.

• Timing: The company is in a strong growth phase, but the exit of PE funds suggests they believe the valuation is at a peak.
• Insider Behavior: This is a pure exit for major institutional holders (Samara, NHPEA, Kotak).
• Capital Need vs. Liquidity Event: This is clearly a liquidity event for existing shareholders; no fresh capital is coming into the balance sheet.
• Narrative vs. Financial Reality: The "diversified" growth narrative must be balanced against the reality that one product (Supraflex Cruz) is the primary engine of the top line.

Conclusion: This IPO primarily represents a liquidity event for existing shareholders.

Core Strengths: High-growth MedTech niche, global footprint, and proven R&D in high-barrier segments. Major Concerns: Massive revenue concentration in the Supraflex Cruz product, significant litigation (₹1,319.69m), and a pure exit-oriented IPO structure. Suitability: Suitable for investors looking for MedTech exposure who can tolerate high product concentration and litigation risks. Not recommended for conservative investors seeking fresh capital-led growth. Key Metrics to Monitor: Revenue contribution of Supraflex Cruz, outcome of pending litigations, and conversion of PAT to Operating Cash Flow.

Investment Insight: A high-growth MedTech play that is currently a "one-product" story; invest only if you are comfortable with the concentration risk and the PE exit context.